All Access Articles |
- Stoke Therapeutics Aligns with Global Regulatory Agencies for Phase 3 Study of Zorevunersen | 2025-01-07 | PHARMACEUTICAL
- Stoke Therapeutics – FDA Breakthrough for Dravet Syndrome Treatment | 2024-12-07 | PHARMACEUTICAL
- Stoke Therapeutics Prices Public Offering at $13.50 Per Share | 2024-03-29 | PHARMACEUTICAL